Importantly, the implications of statin-mediated PAR-2 modulation may extend beyond the cancer cell itself to include alterations in the surrounding stromal and adipose compartments, particularly peritumoral adipose tissue (PTAT), which is increasingly recognized as a metabolically active and immunologically dynamic contributor to tumour progression. This evidence concerns the gene NR1I2 and cancer.